Polaryx Therapeutics, Inc. PLYX
to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Our therapeutic philosophy
is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic
diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy,
and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs. Our small molecule
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| R&D | $6.3M | $2.8M | — |
| SG&A | $1.6M | $1.5M | — |
| Total operating expenses | $7.8M | $4.4M | — |
| Operating income | -$7.8M | -$4.4M | — |
| Pre-tax income | -$9.0M | -$30.4M | — |
| Net income | -$9.0M | -$30.4M | — |
| EPS, basic | -0.20 | -0.89 | — |
| EPS, diluted | -0.20 | -0.89 | — |
| Shares, diluted (wtd. avg.) | 45.4M | 34.2M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash and equivalents | $5.1M | $4.6M | — |
| Total current assets | $5.2M | $5.0M | — |
| Total assets | $5.2M | $5.0M | — |
| Accounts payable | $470.0K | $72.0K | — |
| Total current liabilities | $605.0K | $289.0K | — |
| Total liabilities | $605.0K | $289.0K | — |
| Retained earnings | -$99.6M | -$90.7M | — |
| Total equity | $4.6M | $4.7M | $1.3M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating cash flow | -$3.9M | -$2.6M | — |
| Stock-based compensation | $4.7M | $2.4M | — |
| Financing cash flow | $4.5M | $7.2M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-033064.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | — | — | — |
| Gross profit | — | — | — |
| Net income | — | -$30.4M | -$9.0M |
Recent filings and events
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Director nominations Dates and mechanics for shareholders proposing directors. Item 5.08
- Other event Item 8.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Regulation FD disclosure Item 7.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |